STUTTGART, Germany I March 20, 2025 I La Merie Publishing released its newest product entitled:
Competitor Analysis: PSMA-Targeted Therapy & Radiodiagnostics
This Competitive Intelligence report about PSMA-Targeted Therapy & Radiodiagnostics provides a competitor evaluation in the field of imaging of PSMA-positive prostate cancer and of PSMA-targeted therapy by radiopharmaceuticals, bispecific antibodies, cell therapy and of antibody-drug conjugates as of March of 2025.
PSMA-targeting is a clinically validated and increasingly commercially successful approach for positron emission tomography (PET) of prostate cancer and for treatment of PSMA-positive metastatic castration-resistant prostate cancer:
- With 2024 sales of US$ 1,058 mln (+24.3% vs 2023), the fluorinated PSMA-targeted PET imaging agent PYLARIFY exceeds US$ 1 billion in net sales and became the first ever blockbuster radiodiagnostic.
- PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent. Lutetium Lu 177 vipivotide tetraxetan is a PSMA-binding ligand bound to a DOTA chelator radiolabeled with lutetium-177. Pluvicto posted 2024 sales of US$ 1,392 mln (+42% vs 2023).
Prostate specific membrane antigen (PSMA) expression is prevalent in prostate cancer, preserved during malignant transformation, and increases in response to anti-androgen therapies, making it a commonly targeted tumor associated antigen for prostate cancer.
PSMA mainly serves as a binding target for delivery of a variety of payloads, including, but not limited to, cytotoxic drugs in antibody-drug conjugates, recruitment of cytotoxic T-cells in bispecific antibodies or directly PSMA-targeted chimeric antigen receptor T-cells or natural killer cells.
PSMA is also an important binding target for delivery of radioactive payloads in targeted radioligand therapy, whereby binding molecules can be small molecules, peptides and antibodies. A variety of radioligands are being evaluated or have already been approved, including lutetium 177, actinium 225, lead 212, cupper 67, terbium 161, and astatine 211.
This product consists of a competitor description and analysis in a tabular format provided as a pdf document which is sent by e-mail within one day, usually within one hour.
The pdf report includes a compilation of marketed and currently active projects in research and development of PSMA-targeted therapies and radiodiagnostics. In addition, the pdf report lists company-specific R&D pipelines of PSMA-targeted therapies and radiodiagnostics.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis reports:
Competitor Analysis reports deliver NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced with hyperlinks to the source of information.
The report “Competitor Analysis: PSMA-Targeted Therapy & Radiodiagnostics” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/competitor-analysis-psma-targeted-therapy-radiodiagnostics/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE:La Merie Publishing
Post Views: 434
STUTTGART, Germany I March 20, 2025 I La Merie Publishing released its newest product entitled:
Competitor Analysis: PSMA-Targeted Therapy & Radiodiagnostics
This Competitive Intelligence report about PSMA-Targeted Therapy & Radiodiagnostics provides a competitor evaluation in the field of imaging of PSMA-positive prostate cancer and of PSMA-targeted therapy by radiopharmaceuticals, bispecific antibodies, cell therapy and of antibody-drug conjugates as of March of 2025.
PSMA-targeting is a clinically validated and increasingly commercially successful approach for positron emission tomography (PET) of prostate cancer and for treatment of PSMA-positive metastatic castration-resistant prostate cancer:
- With 2024 sales of US$ 1,058 mln (+24.3% vs 2023), the fluorinated PSMA-targeted PET imaging agent PYLARIFY exceeds US$ 1 billion in net sales and became the first ever blockbuster radiodiagnostic.
- PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent. Lutetium Lu 177 vipivotide tetraxetan is a PSMA-binding ligand bound to a DOTA chelator radiolabeled with lutetium-177. Pluvicto posted 2024 sales of US$ 1,392 mln (+42% vs 2023).
Prostate specific membrane antigen (PSMA) expression is prevalent in prostate cancer, preserved during malignant transformation, and increases in response to anti-androgen therapies, making it a commonly targeted tumor associated antigen for prostate cancer.
PSMA mainly serves as a binding target for delivery of a variety of payloads, including, but not limited to, cytotoxic drugs in antibody-drug conjugates, recruitment of cytotoxic T-cells in bispecific antibodies or directly PSMA-targeted chimeric antigen receptor T-cells or natural killer cells.
PSMA is also an important binding target for delivery of radioactive payloads in targeted radioligand therapy, whereby binding molecules can be small molecules, peptides and antibodies. A variety of radioligands are being evaluated or have already been approved, including lutetium 177, actinium 225, lead 212, cupper 67, terbium 161, and astatine 211.
This product consists of a competitor description and analysis in a tabular format provided as a pdf document which is sent by e-mail within one day, usually within one hour.
The pdf report includes a compilation of marketed and currently active projects in research and development of PSMA-targeted therapies and radiodiagnostics. In addition, the pdf report lists company-specific R&D pipelines of PSMA-targeted therapies and radiodiagnostics.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis reports:
Competitor Analysis reports deliver NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced with hyperlinks to the source of information.
The report “Competitor Analysis: PSMA-Targeted Therapy & Radiodiagnostics” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/competitor-analysis-psma-targeted-therapy-radiodiagnostics/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE:La Merie Publishing
Post Views: 434
